Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.48 |
| ▸ | GABRE | P78334 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromazepam SCHEMBL43933 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29382152 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29521776 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL17225092 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL8414304 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7377690 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7374778 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7951942 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL14215423 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7477766 | 0.84 | ADRA1A (0.72) | ADRA1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135317-A | Reducing side effects of NMDA antagonists | 西洛斯治疗有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-110573184-B | RNA nanostructures, methods of making and uses thereof | 俄亥俄州立创新基金会 | 2025-05-13 | — | — | CN | disclosed |
| CN-119950517-A | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119907662-A | Fast dissolving soft gel capsule | R·P·谢勒技术有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119816301-A | Enteric coated soft gel capsule | R·P·谢勒技术有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025055893-A1 | PHARMACEUTICAL DOSAGE FORMS AND PREPARATION METHODS THEREOF | Triastek, Inc. (CN) | 2025-03-20 | — | — | WO | disclosed |
| CN-112996519-B | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2025-02-28 | — | — | CN | disclosed |
| CN-119524126-A | Pharmaceutical resinated compositions and methods of making and using the same | 罗兹制药公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-115974835-B | Synthesis method of key intermediate of timonazolam | 湖南复瑞生物医药技术有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114828889-B | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114522152-A | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-114522307-A | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-05-24 | — | — | CN | disclosed |
| US-11320441-B2 | Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114391019-A | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114303204-A | Electronic equipment and method for treating depressive symptoms and depressive disorders by digital therapy | 派尔疗法股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114269334-A | Prevention and treatment of hypoglycemia | 戴尔米德医疗公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114206349-A | Methods for treating neurocognitive disorders, chronic pain and reducing inflammation | 指南针探路者有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-107750177-B | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114126587-A | Composition for preparing microemulsion, their preparation method and application of microemulsion | 株式会社MORESCO | 2022-03-01 | — | — | CN | disclosed |
| CN-113993523-A | Treatment of depression and other various disorders with siloxibin | 指南针探路者有限公司 | 2022-01-28 | — | — | CN | disclosed |